Barr challenges Sanofi-Aventis patents
-
- September
- 25
Barr Pharmaceuticals Inc. said that its Pomona-based generic-drug unit, Barr Laboratories Inc., has challenged the patents listed by Sanofi-Aventis U.S. LLC in connection with its Uroxatral 10mg tablets. Barr applied to the U.S. Food and Drug Administration on June 12 to create a generic version of Uroxatral. On Friday, Sanofi-Aventis filed suit in the U.S. District Court for the District of Delaware to prevent Barr from making its generic drug. Barr said it believes that other companies that have applied to the FDA to make the drug have also been sued. Uroxatral treats benign prostatic hyperplasia and has annual U.S. sales of about $140 million, Barr said, citing data from IMS Health.
This entry was posted
on Tuesday, September 25th, 2007 at 5:09 pm by Julie Moran Alterio.
You can follow any responses to this entry through the RSS 2.0 feed.
Share and Enjoy: 
| 
Print
| 
Email
